Quantifying cancer absolute risk and cancer mortality in the presence of competing events after a myotonic dystrophy diagnosis

PLoS ONE

Volumn 8, Issue 11, 2013, Pages

  Gadalla, Shahinaz M ^a   Pfeiffer, Ruth M ^a   Kristinsson, Sigurdur Y ^b,c   Björkholm, Magnus ^b   Hilbert, James E ^d   Moxley III, Richard T ^d   Landgren, Ola ^a   Greene, Mark H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ICELAND   (Iceland)

^d UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CANCER INCIDENCE; CANCER MORTALITY; CANCER RISK; CANCER SURVIVAL; CHILD; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE REGISTRY; FEMALE; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; NATIONAL HEALTH ORGANIZATION; ONSET AGE; PRESCHOOL CHILD; QUANTITATIVE ANALYSIS; RISK ASSESSMENT; SCHOOL CHILD; SEX DIFFERENCE; YOUNG ADULT;

ADOLESCENT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; DENMARK; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; MYOTONIC DYSTROPHY; NEOPLASMS; REGISTRIES; RISK; SWEDEN; YOUNG ADULT;

EID: 84893346501     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0079851     Document Type: Article

References (26)

1. Brook JD, McCurrach ME, Harley HG, Buckler AJ, Church D et al. (1992) Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3' end of a transcript encoding a protein kinase family member. Cell 69: 385. doi: 10.1016/0092-8674(92)90440-N. PubMed: 15682521310900.
2. Fu YH, Pizzuti A, Fenwick RG Jr., King J, Rajnarayan S et al. (1992) An unstable triplet repeat in a gene related to myotonic muscular dystrophy. Science 255: 1256-1258. doi:10.1126/science.1546326. PubMed: 1546326.
3. Mahadevan M, Tsilfidis C, Sabourin L, Shutler G, Amemiya C et al. (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3' untranslated region of the gene. Science 255: 1253-1255. doi:10.1126/science.1546325. PubMed: 1546325.
4. Ranum LP, Day JW (2002) Myotonic dystrophy: clinical and molecular parallels between myotonic dystrophy type 1 and type 2. Curr Neurol Neurosci Rep 2: 465-470. doi:10.1007/s11910-002-0074-6. PubMed: 12169228.
5. Liquori CL, Ricker K, Moseley ML, Jacobsen JF, Kress W et al. (2001) Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 293: 864-867. doi:10.1126/science.1062125. PubMed: 11486088. (Pubitemid 32743976)
6. Harper PS (2001) Myotonic dystrophy. Philadelphia: WB Saunders.
7. Du H, Cline MS, Osborne RJ, Tuttle DL, Clark TA et al. (2010) Aberrant alternative splicing and extracellular matrix gene expression in mouse models of myotonic dystrophy. Nat Struct Mol Biol 17: 187-193. doi: 10.1038/nsmb.1720. PubMed: 20098426. nsmb.1720
8. Osborne RJ, Lin X, Welle S, Sobczak K, O'Rourke JR et al. (2009) Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet 18: 1471-79. doi:10.1093/hmg/ddp058. PubMed: 19223393.
9. Vihola A, Bachinski LL, Sirito M, Olufemi SE, Hajibashi S et al. (2010) Differences in aberrant expression and splicing of sarcomeric proteins in the myotonic dystrophies DM1 and DM2. Acta Neuropathol, 119: 20066428.
10. de Die-Smulders CE, Höweler CJ, Thijs C, Mirandolle JF, Anten HB et al. (1998) Age and causes of death in adult-onset myotonic dystrophy. Brain 121 (8): 1557-1563. doi:10.1093/brain/121.8.1557. PubMed: 9712016. (Pubitemid 28349907)
11. Groh WJ, Groh MR, Shen C, Monckton DG, Bodkin CL et al. (2011) Survival and CTG repeat expansion in adults with myotonic dystrophy type 1. Muscle Nerve 43: 648-651. doi:10.1002/mus.21934. PubMed: 21484823.
12. Mathieu J, Allard P, Potvin L, Prévost C, Bégin P (1999) A 10-year study of mortality in a cohort of patients with myotonic dystrophy. Neurology 52: 1658-1662. doi:10.1212/WNL.52.8.1658. PubMed: 10331695. (Pubitemid 29220644)
13. Mladenovic J, Pekmezovic T, Todorovic S, Rakocevic-Stojanovic V, Savic D, Romac S et al. (2006) Survival and mortality of myotonic dystrophy type 1 (Steinert's disease) in the population of Belgrade. Eur J Neurol 13: 451-454. doi:10.1111/j.1468-1331.2006.01261.x. PubMed: 16722967. (Pubitemid 43823357)
14. Gadalla SM, Lund M, Pfeiffer RM, Gørtz S, Mueller CM et al. (2011) Cancer risk among patients with myotonic muscular dystrophy. JAMA 306: 2480-2486. doi:10.1001/jama.2011.1796. PubMed: 22166607.
15. Win AK, Perattur PG, Pulido JS, Pulido CM, Lindor NM (2012) Increased Cancer Risks in Myotonic Dystrophy. Mayo Clin Proc, 87: S0025-S6196. PubMed: 22237010. doi:10.1016/j.mayocp.2011.09.005
16. (1998) Patientregistret 1987-1996: Kvalitet och innehåll (Swedish).
17. Nilsson AC, Spetz CL, Carsjo K, Nightingale R, Smedby A (1994) Slutenvardsregistrets tillforlitlighet. Diagnosuppgifterna battre an sitt rykte. (The reliability of the Hospital Discharge Register. the discharge diagnoses are more correct than the common belief). Lakartidningen 91: 598-605.
18. Mattsson B, Wallgren A (1984) Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 23: 305-313. doi:10.3109/02841868409136026. PubMed: 6095600. (Pubitemid 15028463)
19. Turesson I, Linet MS, Björkholm M, Kristinsson SY, Goldin LR et al. (2007) Ascertainment and diagnostic accuracy for hematopoietic lymphoproliferative malignancies in Sweden 1964-2003. Int J Cancer 121: 2260-2266. doi:10.1002/ijc.22912. PubMed: 17583571. (Pubitemid 47585607)
20. Marubini E, Valsecchi MG (1995) Analysing Survival Data from Clinical Trials and Observational Studies. John Wiley & Sons Ltd.
21. Satagopan JM, Ben-Porat L, Berwick M, Robson M, Kutler D, Auerbach AD (2004) A note on competing risks in survival data analysis. Br J Cancer 91: 1229-1235. doi:10.1038/sj.bjc.6602102. PubMed: 15305188. (Pubitemid 39424779)
22. Das M, Moxley RT III, Hilbert JE, Martens WB, Letren L et al. (2012) Correlates of tumor development in patients with myotonic dystrophy. J Neurol, 259: 2161-6. doi:10.1007/s00415-012-6476-8. PubMed: 22619053.
23. The National Board of Health and Welfare (2008) Cancer Incidence in Sweden 2007. Available: http://www.socialstyrelsen.se/lists/artikelkatalog/ attachments/8715/2008-125-16-200812516-rev2.pdf. Accessed: 28 July 2013.
24. Organisation for Economic Co-operation and Development (OECD) Health Data 2011 (2012) Life expectancy at birth, total population. Available: http://www.oecd-ilibrary.org/social-issues-migration-health/life-expectancy-at- birth-total-population-2012-1-lifexpy-total-table-2012-1-en. Accessed: 15 January 2013.
25. Mohamed S, Pruna L, Kaminsky P (2013) Increasing risk of tumors in myotonic dystrophy type 1. Presse Med: S0755-S4982. doi:10.1016/j.lpm.2013.01. 052.
26. Mueller CM, Hilbert JE, Martens W, Thornton CA, Moxley RT III et al. (2009) Hypothesis: neoplasms in myotonic dystrophy. Cancer Causes Control